Apex has been appointed by by BrightEdge LLC, the impact investment and venture capital arm of the American Cancer Society (ACS) to provide fund administration services to the ACS Impact Venture Fund. BrightEdge invests in for-profit early-stage companies that are developing cutting-edge cancer-focused therapies, diagnostics, devices, and technologies. Financial returns generated from investments will be reinvested in the fund and/or returned to ACS.
As a firm supporter of ACS’s mission, Apex has pledged a substantial percentage of the fee revenue received from its role as fund administrator for BrightEdge and the fund as an ongoing donation to ACS.